secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0001823239-22-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M
--------------------------------------------------------------------------------

- Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).
- FY2021 revenue $799.2M (+181% YoY); net income $469.3M; adjusted EBITDA $582.8M.
- Nucleic Acid Production segment Q4 revenue $212.5M (+173% YoY) driven by CleanCap demand for mRNA vaccines.
- 2022 revenue guidance raised to $920M-$960M, implying 15-20% growth over 2021 record.
- Completed debt repricing saving ~$6.8M annually in interest; acquired MyChem for ultra-pure nucleotides.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/0001823239-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000008/mrvi-20220223.htm
  HTML page:      https://secwatch.observer/filing/0001823239-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer